23P - Real-life experience with nivolumab and pembrolizumab in patients(pts) with advanced non-small cell lung cancer(NSCLC): efficacy and safety analysi...

Date 08 December 2017
Event ESMO Immuno-Oncology Congress 2017
Session Lunch & Poster Display session
Topics Neuroendocrine Cancers
Presenter Dilara Akhoundova Sanoyan
Citation Annals of Oncology (2017) 28 (suppl_11): xi6-xi29. 10.1093/annonc/mdx711
Authors D. Akhoundova Sanoyan1, A. Siebenhüner1, R. Delaloye1, L. Bankel1, T.D.L. Paulino2, A. Curioni1
  • 1Medical Oncology, University Hospital Zurich, 8091 - Zurich/CH
  • 2Institute Of Experimental Immunology, University of Zurich, 8057 - Zurich/CH

Abstract

Background

Nivolumab showed an overall survival(OS) benefit compared with docetaxel (12.2 vs 9.4 months(m), p = 0.002) in pts with non-sqamous NSCLC and a better progression-free survival(PFS) and OS(42% vs 24%, at 1 year, p 

Methods

Retrospective review of 70 consecutive pts with stage IIIB and IV NSCLC treated with nivolumab or pembrolizumab outside of clinical trials from June 2015 until August 2017 at the University Hospital of Zürich.OS and PS were calculated with Kaplan-Meier function, while differences between subgroups were assessed with log-rank test.

Results

63(90%) pts treated with nivolumab, 56(88.9%) of them in 2nd line, and 7(10%) with pembrolizumab, 5(71.4%) of them in 1st line. Median number of cycles was 11(range(r): 1-50) for nivolumab and 3(r: 1-10) for pembrolizumab. Median age was 64.5 years (r: 39.0-89.4). In the nivolumab cohort: 48(76.2%)pts had non-squamous and 15(23.8%) squamous NSCLC, 25 (39.7%) had brain metastases(mts); median OS based on 22 events was 16.5m(95% CI: 11.5-21.4), 14.2m(95%CI:11.2-17.2) without brain mts vs not reached with brain mts, p = 0.86; median PFS, based on 42 events was 5.5 m(95% CI: 3.0-8.0). In the pembrolizumab cohort: 6 pts(85.7%) had non-squamous NSCLC, 3(42.9%) brain mts; median OS was not reached; median PFS, based on 5 events was 1.4 m(95% CI:0.1-3.1). Immune-mediated adverse effects in 8 (11.4%)pts. Grade 3 pneumonitis in 2 pts, one with treatment discontinuation after 2 cycles and complete response 20m later, other with partial response after 38 cycles.

Conclusions

OS of this pts' cohort treated with nivolumab is superior to previous published data (16.5 vs 12.2 m). Almost 40% of pts had brain mts, indicating that also in this cohort the treatment is effective. The cohort of pts treated with pembrolizumab is still too small for evaluation. Radiological and molecular analysis is ongoing.

Clinical trial identification

Legal entity responsible for the study

University Hospital Zurich

Funding

None

Disclosure

All authors have declared no conflicts of interest.